Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823506 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL22127844 | 0.86 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127873 | 0.86 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL29482638 | 0.86 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127898 | 0.85 | KMT2A (0.57) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127899 | 0.85 | KMT2A (0.57) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL17746952 | 0.85 | KMT2A (0.65) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL17746951 | 0.85 | KMT2A (0.65) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL30905448 | 0.85 | KMT2A (0.65) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL29482146 | 0.85 | KMT2A (0.62) | KMT2AEPHX2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130409-A1 | Method for the Solid-Phase Synthesis of Cyclic Pentapeptides | Alsonex Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130409-A1 | Method for the Solid-Phase Synthesis of Cyclic Pentapeptides | ARG1, PNISR, HRH3 | KMT2A 1314/4885EPHX2 593/4885CASP3 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.